Search research articles
Contact Us
Filters
Showing results (171-180 of 184) with videos related to
Page
of 19
Sort By:
Gynecologic Oncology
|
January 3, 2009
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
Amanda Nickles Fader, Christa Nagel, Allison E Axtell, et al.
American Journal of Obstetrics and Gynecology
|
February 26, 2022
Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study
Phuong L Mai, Austin Miller, Amanda Black, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2025
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Jung-Min Lee, Austin Miller, Peter G Rose, et al.
Gynecologic Oncology
|
February 5, 2021
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study
Kimberly K Leslie, Virginia L Filiaci, Adrianne R Mallen, et al.
Gynecologic Oncology
|
August 16, 2017
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience
Kate E Oliver, William E Brady, Michael Birrer, et al.
Cancer
|
April 15, 2023
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Mansoor R Mirza, Antonio González-Martín, Whitney S Graybill, et al.
The Journal of Experimental Medicine
|
August 26, 2017
CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors
Caner Saygin, Andrew Wiechert, Vinay S Rao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2019
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Joan L Walker, Mark F Brady, Lari Wenzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Jung-Min Lee, Mark F Brady, Austin Miller, et al.
Clinical Therapeutics
|
July 17, 2024
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer
Bradley J Monk, Ignacio Romero, Whitney Graybill, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 184) with videos related to
Sort By:
Page
of 19
Gynecologic Oncology
|
January 3, 2009
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
Amanda Nickles Fader, Christa Nagel, Allison E Axtell, et al.
American Journal of Obstetrics and Gynecology
|
February 26, 2022
Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study
Phuong L Mai, Austin Miller, Amanda Black, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2025
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Jung-Min Lee, Austin Miller, Peter G Rose, et al.
Gynecologic Oncology
|
February 5, 2021
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study
Kimberly K Leslie, Virginia L Filiaci, Adrianne R Mallen, et al.
Gynecologic Oncology
|
August 16, 2017
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience
Kate E Oliver, William E Brady, Michael Birrer, et al.
Cancer
|
April 15, 2023
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Mansoor R Mirza, Antonio González-Martín, Whitney S Graybill, et al.
The Journal of Experimental Medicine
|
August 26, 2017
CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors
Caner Saygin, Andrew Wiechert, Vinay S Rao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2019
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Joan L Walker, Mark F Brady, Lari Wenzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Jung-Min Lee, Mark F Brady, Austin Miller, et al.
Clinical Therapeutics
|
July 17, 2024
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer
Bradley J Monk, Ignacio Romero, Whitney Graybill, et al.
Page
of 19